Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAABAK versus FLUCON for birch pollen allergic conjunctivitis in an environmental exposure chamber
2017-001838-26Phase 4Completed
- Sponsor
- Laboratoires Théa
- Start
- Jan 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sodium cromoglycate and fluconazole in allergic conjunctivitis (AC) (2 arms), sponsored by Laboratoires Théa. Primary endpoint: Allergen quantity needed to induce a positive conjunctival response. Started Jan 2021; status: completed.
02
Drugs
sodium cromoglycatefluconazole
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2017-001838-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001838-26.